Masitinib is a highly selective tyrosine kinase inhibitor (TKI) approved for veterinary use across the European Union, the United States, and Japan. By targeting specific signaling pathways, it provides a sophisticated therapeutic approach for managing cancers, chronic inflammation, and immune-mediated disorders in companion animals.

Treatment of Mast Cell Tumors

Masitinib is a cornerstone in veterinary oncology, particularly for Mast Cell Tumors (MCTs)-one of the most prevalent canine cancers. Its targeted action offers several clinical advantages:

Management of Inflammatory Conditions

Beyond oncology, Masitinib modulates inflammatory pathways, making it an essential tool for treating chronic conditions in aging pets:

Immune-Mediated Disorders

Masitinib helps regulate abnormal immune responses that would otherwise lead to tissue damage. It is frequently applied in treating:

▸ Idiopathic Thrombocytopenia: Preventing immune-mediated platelet destruction.

▸ IMHA: Reducing the destruction of red blood cells by the immune system.

Clinical Value in Practice

Summary

Masitinib represents a significant advancement in contemporary veterinary medicine. By improving clinical outcomes and enhancing the quality of life for dogs and cats, it stands as a trusted treatment option for complex and chronic conditions.